260 related articles for article (PubMed ID: 26125109)
1. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease.
Bressler B; Panaccione R; Fedorak RN; Seidman EG
Can J Gastroenterol Hepatol; 2015 Oct; 29(7):369-72. PubMed ID: 26125109
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.
Heida A; Park KT; van Rheenen PF
Inflamm Bowel Dis; 2017 Jun; 23(6):894-902. PubMed ID: 28511198
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease.
Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.
Ikhtaire S; Shajib MS; Reinisch W; Khan WI
J Gastroenterol; 2016 May; 51(5):434-46. PubMed ID: 26897740
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.
Zhang W; Wong CH; Chavannes M; Mohammadi T; Rosenfeld G
BMJ Open; 2019 Apr; 9(4):e027043. PubMed ID: 30987989
[TBL] [Abstract][Full Text] [Related]
6. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
7. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
8. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.
D'Amico F; Rubin DT; Kotze PG; Magro F; Siegmund B; Kobayashi T; Olivera PA; Bossuyt P; Pouillon L; Louis E; Domènech E; Ghosh S; Danese S; Peyrin-Biroulet L
United European Gastroenterol J; 2021 May; 9(4):451-460. PubMed ID: 33961734
[TBL] [Abstract][Full Text] [Related]
9. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Konikoff MR; Denson LA
Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
[TBL] [Abstract][Full Text] [Related]
10. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.
Motaganahalli S; Beswick L; Con D; van Langenberg DR
Intern Med J; 2019 Jan; 49(1):94-100. PubMed ID: 29962008
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
Hradsky O; Ohem J; Mitrova K; Durilova M; Kotalova R; Nevoral J; Kolho KL; Bronsky J
Clin Lab; 2014; 60(12):1993-2000. PubMed ID: 25651733
[TBL] [Abstract][Full Text] [Related]
12. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
13. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
[TBL] [Abstract][Full Text] [Related]
15. Calprotectin or Lactoferrin: Do They Help.
Wright EK
Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
17. Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study.
Du L; Foshaug R; Huang VW; Kroeker KI; Dieleman LA; Halloran BP; Wong K; Fedorak RN
J Clin Gastroenterol; 2018 Mar; 52(3):235-240. PubMed ID: 28009684
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
Sipponen T; Kolho KL
Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
[TBL] [Abstract][Full Text] [Related]
19. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin as a promising marker of inflammatory diseases.
Paduchova Z; Durackova Z
Bratisl Lek Listy; 2009; 110(10):598-602. PubMed ID: 20017448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
